Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized study of lenvatinib plus pembrolizumab plus chemotherapy in metastatic gastric/gastroesophageal adenocarcinoma
2020-001990-53Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Oct 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of lenvatinib and pembrolizumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC) (2 arms), sponsored by Merck & Co. Primary endpoints: Dose-limiting toxicities in Part 1 and Objective response rate in Part 2. Started Oct 2020; status: active.
02
Drugs
lenvatinibpembrolizumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2020-001990-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001990-53.